CCDC85C Inhibitors

The category of CCDC85C Inhibitors encompasses a range of chemicals that may indirectly affect the function of the coiled-coil domain-containing protein 85C through modulation of various cellular pathways and processes. These compounds do not directly target CCDC85C but can influence its activity or the activity of interacting proteins by altering the cellular environment or specific signaling cascades. For instance, Wortmannin and LY294002 are phosphoinositide 3-kinase (PI3K) inhibitors that can disrupt downstream signaling, potentially affecting the cellular context in which CCDC85C operates. Similarly, the inhibition of MAP kinase pathways through compounds such as U0126, SB203580, and SP600125 can change the phosphorylation status of proteins that may interact with CCDC85C, thereby altering its function.

In addition, inhibiting mTOR with Rapamycin can have widespread effects on cell growth and protein synthesis, which can indirectly impact the role of CCDC85C in the cell. Bortezomib and Thapsigargin exert their effects by inducing cellular stress, which can perturb the stability and interactions of proteins, including those associated with CCDC85C. Tunicamycin and Cycloheximide disrupt protein folding and synthesis, respectively, which can have consequences for protein complexes that include CCDC85C. PD98059 targets the MEK pathway, again potentially influencing the proteins that work in conjunction with CCDC85C. Lastly, ZM-447439's inhibition of Aurora kinases affects cell cycle progression, which can alter the cellular environment and indirectly impact the function of CCDC85C. These chemicals provide insights into complex cellular pathways and highlight the interconnectivity of signaling networks that can affect the function of proteins like CCDC85C.